Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Kyle

Internal Medicine Okatie, SC Doctor of Osteopathy

NPI 1770758351 CMS profile 307067

14 Okatie Center Blvd S, Suite 101, Okatie, SC 29909

Open in the dashboard

General payments

$2,017

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Kyle of Okatie, SC is reported in the CMS Open Payments database as having received $2,017 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $396 19
2024 General $535 26
2023 General $399 19
2022 General $138 9
2021 General $143 9
2020 General $112 8
2019 General $293 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Kyle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Kyle were reported at $396. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Kyle Internal Medicine median Middle half National median
2019 $293 $159 $48–$570 $163
2020 $112 $119 $33–$402 $114
2021 $143 $135 $37–$521 $132
2022 $138 $141 $42–$496 $149
2023 $399 $149 $45–$519 $160
2024 $535 $154 $47–$537 $164
2025 $396 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $358 18 payments
  2. Novo Nordisk Inc $305 19 payments
  3. Amgen Inc. $234 12 payments
  4. Lilly USA, LLC $182 11 payments
  5. AstraZeneca Pharmaceuticals LP $145 8 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $98 5 payments
  7. Boston Scientific Corporation $97 4 payments
  8. Exact Sciences Corporation $76 5 payments
  9. Sanofi-Aventis U.S. LLC $61 2 payments
  10. Kowa Pharmaceuticals America, Inc. $47 4 payments
  11. Other $413 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,017 108 payments
Products named General payments · program years 2019–2025
  1. Ozempic $224 14 payments
  2. RYBELSUS $209 13 payments
  3. Repatha $174 9 payments
  4. Otezla $135 7 payments
  5. ELIQUIS $131 7 payments
  6. JARDIANCE $109 7 payments
  7. FARXIGA $105 6 payments
  8. TRULICITY $104 8 payments
  9. PREVNAR 20 $67 3 payments
  10. COMIRNATY $65 3 payments
  11. Other $1,644 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 152 drugs

Part D claims

15,803

Median for Internal Medicine: 777

Drug cost

$1,180,310

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 116 $148,026
Mounjaro Tirzepatide Brand 116 $140,252
Ozempic Semaglutide Brand 95 $127,297
Jardiance Empagliflozin Brand 82 $117,559
Farxiga Dapagliflozin Propanediol Brand 69 $91,960
Trulicity Dulaglutide Brand 52 $71,383
Januvia Sitagliptin Phosphate Brand 50 $67,167
Tresiba Flextouch U-200 Insulin Degludec Brand 42 $51,070
Tradjenta Linagliptin Brand 36 $38,802
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 31 $31,501

The 10 drugs with the highest cost, of 152 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$330,985

Of which drugs: $28,128

Medicare patients

1,102

Average age 75

Services billed

4,523

517 women, 585 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 45%
Ischemic heart disease 21%
Diabetes 20%
Chronic kidney disease 20%
Cancer 19%
Atrial fibrillation 17%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 72 72 $20,782
Vaccine for influenza for injection into muscle 90653 Office 87 87 $7,118

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $39
$39 69 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $35
$35 — —
KRYSTEXXA
  • Amgen Inc. $33
$33 — —
ELIQUIS
  • PFIZER INC. $29
$29 116 —
Otezla
  • Amgen Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record